However, the large multicenter study by Poullenot et al. [28] showed that an interval < 12 months between the diagnosis of cancer and the start of immunosuppressants can be associated with a higher rate of incident cancer (HR 2.89, p = 0.01), independent from the type of immunosuppressants (including AZA, MTX, anti-TNFα, and VDZ). This evidence concerns the gene TNF and cancer.